Abstract
Fluoroquinolones have been associated with peripheral sensory disorders and weakness, especially in patients with underlying myasthenia gravis or myasthenia-like Eaton-Lambert syndrome. Trovafloxacin is a relatively new quinolone for which these side effects have not been described. We report a case of diffuse weakness due to a demyelinating polyneuropathy that began after initiation of trovafloxacin in a patient without an underlying neurologic disorder.
MeSH terms
-
Anti-Infective Agents / adverse effects*
-
Demyelinating Diseases / chemically induced*
-
Electromyography / drug effects
-
Fluoroquinolones*
-
Follow-Up Studies
-
Humans
-
Leg / innervation
-
Male
-
Middle Aged
-
Muscle Weakness / chemically induced*
-
Muscle, Skeletal / drug effects
-
Muscle, Skeletal / innervation
-
Naphthyridines / adverse effects*
-
Neural Conduction / drug effects
-
Polyneuropathies / chemically induced*
Substances
-
Anti-Infective Agents
-
Fluoroquinolones
-
Naphthyridines
-
trovafloxacin